Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis

Bibliography

• Prevention and management of osteoporosis. WHO Scientific Group. World Health Organization Technical Report Series 2003;921:1-164
   PubMed Web of Science ®Google Scholar
• Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005;51(2):113-26
   PubMed Web of Science ®Google Scholar
• Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004;5(10):1086-93
   PubMedGoogle Scholar
• Patat A, McKeand W, Baird-Bellaire S, et al. Absolute/relative bioavailability of bazedoxifene acetate in healthy postmenopausal women [abstractP43]. Clin Pharmacol Ther 2003;73
   Google Scholar
• Ermer J, Kotake A, McKeand W, et al. Clinical pharmacology of a novel tissue selective estrogen (WAY-140424) in postmenopausal women following administration for 30 days [abstractP94]. J Bone Miner Res 2000;17M
   Google Scholar
• Chandrasekaran A, Ermer J, McKeand W, et al. Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women [abstractP47]. Clin Pharmacol Ther 2003;73
   Google Scholar
• Crabtree JS, Peano BJ, Zhang X, et al. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 2008;287(1-2):40-6
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146(9):3999-4008
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, Bex F. Bazedoxifene + conjugated estrogens: a balanced combination to provide optimal “ Estrogenic ” safety and efficacy [abstractS272]. J Bone Miner Res 2003;18(Suppl 2)
   Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-26
   PubMed Web of Science ®Google Scholar
• Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44(11):1654-7
   PubMed Web of Science ®Google Scholar
• Smith SY, Minck SY, Jolette J, et al. Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkey [abstractS174]. J Bone Miner Res 2005;20(Suppl 1)
   Google Scholar
• Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93(4):558-65
   PubMed Web of Science ®Google Scholar
• Katovich MJ, Simpkins JW, Barney CC. Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats. Brain Res 1987;426(1):55-61
   PubMedGoogle Scholar
• Ciriza I, Carrero P, Azcoitia I, et al. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J Neurobiol 2004;61(2):209-21
   PubMedGoogle Scholar
• Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105(6):1397-404
   PubMed Web of Science ®Google Scholar
• van Duren D, Ronkin S, Pickar J, Constantine G. Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstractS88-S89]. Fertil Steril 2006;86(Suppl 1)
   Google Scholar
• Itabashi I, Ohta H, Ebede B, Constantine G. A double-blind, placebo-controlled, dose-response study of bazedoxifene in Japanese postmenopausal women with osteoporosis [abstractP79]. J Bone Miner Res 2008;23
   Google Scholar
• Boudes P, Ronkin S, Korner P, et al. Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain [abstractS4] Osteoporos Int 2003;14
   Google Scholar
• Bachmann G, Crosby U, Feldman RA, et al. Vasomotor effects of bazedoxifene in nonflushing postmenopausal women [abstract P-10]. Menopause 2008;15(6):1212
   Google Scholar
• Chesnut CH, Christiansen C, Hoeck HC, et al. Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis [abstractW387]. J Bone Miner Res 2007;22
   Google Scholar
• Miller CP, Christiansen C, Hoeck HC, et al. Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis. Results of a 2-year, phase III, placebo- and active-controlled study [abstract1209]. J Bone Miner Res 2007;22
   Google Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23(4):525-35
   PubMed Web of Science ®Google Scholar
• Adachi JD, Chesnut CH, Brown JP, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial [abstractW385]. J Bone Miner Res 2007;22
   PubMedGoogle Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-34
   PubMed Web of Science ®Google Scholar
• New Tissue-Selective Estrogen Complex Shows Improvement in Bone Density; 2007 http://www.medscape.com/viewarticle/558305
   Google Scholar
• Bayes M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008;30(1):67-99
   PubMedGoogle Scholar